Amgen
Corporate Headquarters
One Amgen Center Drive
Thousand Oaks
California
91320-1799
United States
Tel: 805-447-1000
Fax: 805-447-1010
Website: http://careers.amgen.com/
Email: talentacquisitioninquiries@amgen.com
About Amgen
We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.
We live the mission.
We win together.
We thrive on continual challenge.
Our team of 22,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.
At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.
Connect with us to explore how you can Win, Live, and Thrive at Amgen.
Defy Imagination
2521 articles about Amgen
-
7 Top Companies Hiring Regulatory Jobs
3/14/2024
Looking for regulatory jobs in the biopharma industry? Check out the BioSpace list of seven top companies hiring for these critical roles. -
Amgen Presents New Research on Otezla® (Apremilast) at AAD 2024
3/9/2024
Amgen announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis.
-
Amgen Announces 2024 Second Quarter Dividend
3/6/2024
Amgen announced that its Board of Directors declared a $2.25 per share dividend for the second quarter of 2024.
-
Despite the changing landscape in biopharma, many companies are still recruiting. If you’re looking to make a career change, here are 12 biopharma companies hiring on BioSpace now.
-
Sandoz’s two interchangeable biosimilars, Jubbonti and Xgeva, are poised to challenge Amgen’s blockbuster bone drug denosumab. However, no launch details were announced Tuesday due to ongoing patent litigation.
-
After oncology and neuroscience headlined biopharma investment in 2023, experts anticipate increased interest in the autoimmune and obesity spaces this year.
-
Amgen to Present at the 44th Annual TD Cowen Health Care Conference
2/29/2024
Amgen will present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Tuesday, March 5, 2024.
-
Amgen Opens State-of-the-Art Biomanufacturing Site in Central Ohio
2/26/2024
Amgen announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date.
-
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
2/19/2024
Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline.
-
Amgen to Present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
2/9/2024
Amgen will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. ET on Wednesday, Feb. 14, 2024.
-
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
2/6/2024
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022.
-
Phase I results published Monday suggest Amgen’s investigational weight-loss drug MariTide produces longer-lasting effects than GLP-1s currently on the market.
-
AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
2/1/2024
Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024, after the close of the U.S. financial markets.
-
deCODE genetics: A sequence variant that increases risk of pregnancy loss
1/29/2024
Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from Iceland, Denmark, and the USA published a study in Nature Structural & Molecular Biology titled "Variant in the synaptonemal complex protein SYCE2 associates with pregnancy loss through effects on recombination".
-
The regulator concluded that Prolia (denosumab) increases the risk of severe hypocalcemia, which may result in hospitalization and could trigger life-threatening events or even lead to death.
-
AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
1/3/2024
Amgen (NASDAQ:AMGN) will present at the 2024 J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Monday, January 8, 2024.
-
Amgen Provides Regulatory Update on Status of LUMAKRAS® (Sotorasib)
12/26/2023
Amgen announced that the U.S. Food and Drug Administration has completed its review of the company's supplemental New Drug Application seeking full approval of LUMAKRAS®.
-
The year may be coming to a close, but there's no holiday break for the FDA, which will release five regulatory verdicts over the next two weeks.
-
Amgen Announces Executive Appointments to Accelerate Innovation
12/14/2023
Amgen announced two changes to its senior leadership team in the areas of research and development and technology, underscoring the advancement of the company's robust pipeline and its commitment to ongoing scientific and technological innovation.
-
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
12/13/2023
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics License Application (BLA) for tarlatamab.